Brief Title
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
Official Title
To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )
Brief Summary
The purpose of this study is to To assess the correlation between the predictive factor of
vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate,
and overall survival) .
Detailed Description
This is a randomized controlled retrospective study through Examination of paraffin blocks of
the patient selected to be included in the study for assessment of the selected vascularity
marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended
for qualified laboratories to qualitatively identify by light microscopy the presence of
associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using
Immunohistochemistry test methods.
Study Type
Observational
Primary Outcome
to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival
Secondary Outcome
assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74
Condition
Malignant Pleural Mesotheliomas
Intervention
marker CD74 and vascular endothelial growth factor VEGF
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
50
Start Date
October 2015
Completion Date
May 2016
Primary Completion Date
May 2016
Eligibility Criteria
Inclusion Criteria:
- Histopathological confirmation of malignant pleural mesothelioma .
- Full clinical data.
- Availability for follow up: Personal communication will be attempted in order to
collect missing information.
3-The files of all patients will be reviewed to analyze the following :
- Operative data if done .
- Pathological review and immunohistochemistry.
- Laboratory investigations: (routine investigations: complete blood picture,liver and
renal function test)
- Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).
- Treatment protocols applied: Radiotherapy and Chemotherapy.
- Response and survival after treatment .
Exclusion Criteria:
- cases not receive chemotherapy ,on available of evaluation after treatment
Gender
All
Ages
39 Years - 84 Years
Accepts Healthy Volunteers
No
Contacts
Amr S Saad, MD, ,
Location Countries
Egypt
Location Countries
Egypt
Administrative Informations
NCT ID
NCT02603315
Organization ID
DR-81
Responsible Party
Principal Investigator
Study Sponsor
Ain Shams University
Study Sponsor
Amr S Saad, MD, Study Director, Ain Shams University
Verification Date
October 2015